Clinical Efficacy of Tofacitinib in the Treatment of Rheumatoid Arthritis Secondary to Sjogrensyndrome
Objective To explore and analyze the therapeutic effect of tofacitinib in patients with rheumatoid arthritis secondary to sjogrensyndrome.Methods 72 patients with rheumatoid arthritis secondary sjogren's syndrome admitted to Taizhou Second People's Hospital from May 2021 to February 2023 were selected as the study subjects,and they were divided into two groups according to envelope random method.The reference group(36 cases)received sole methotrexate treatment,and the study group(36 cases)received combined tofacatib treatment,and the therapeutic ef-fects of the two groups were compared.Results After treatment,the number of swollen joints(3.8±1.0)and tender joints(6.3±2.0)in the study group was lower than that in the reference group(4.7±1.6)and(8.6±2.1),and the differ-ences were statistically significant(t=2.862,4.759,both P<0.05).The effective rate of rheumatoid arthritis treatment in the study group was 97.22%,higher than that in the reference group(77.78%),and the difference was statistically significant(χ2=6.222,P=0.013).The effective rate of sjogren's syndrome treatment in the study group was 97.22%,higher than that in the reference group(80.56%),and the difference was statistically significant(χ2=5.062,P=0.024).Conclusion The use of tofacatib in the treatment of patients with rheumatoid arthritis secondary sjogren's syndrome can achieve very precise curative effect,alleviate the patient's condition,reduce the clinical discomfort symptoms of patients,and improve their quality of life.At the same time,it can adjust the body state of the patient,effectively re-duce the degree of joint tenderness of the patient,so that the patient can return to normal work and life.
NETL
NSTL
万方数据
